Transcutaneous Auricular Vagus Nerve Stimulation towards Visually Induced Motion Sickness Reduction: A Pilot Study.

Transcutaneous auricular vagus nerve stimulation (taVNS) is a novel neuromodulation application for vagal afferent stimulation. Owing to its non-invasive nature, taVNS is a potent therapeutic tool for a diverse array of diseases and disorders that ail us. Herein, we investigated taVNS-induced effects on neural activity of participants during visually induced motion sickness. 64-channel electroencephalography (EEG) recordings were obtained from 15 healthy participants in a randomized, within-subjects, cross-over design during sham and taVNS conditions. To assess motion sickness severity, we used the motion sickness assessment questionnaire (MSAQ). We observed that taVNS attenuated theta (4-8 Hz) brain activity in the right frontal, right parietal and occipital cortices when compared to sham condition. The total MSAQ scores, and central, peripheral and sopite MSAQ categorical scores were significantly lower after taVNS compared to sham. These findings reveal for the first time the potential therapeutic role of taVNS toward counter-motion sickness, and suggest that taVNS may be reliable in alleviating symptoms of motion sickness in real-time, non-pharmacologically.Clinical relevance- This suggests taVNS potential to offset motion sickness-induced nausea; which may be of translational value to counter e.g., chemotherapy-induced nausea.

Vibro-motor Reprocessing Therapy towards Managing Motion Sickness Reduction: Evidence from EEG.

This study examines the neural activities of participants undergoing vibro-motor reprocessing therapy (VRT) while experiencing motion sickness. We evaluated the efficacy of vibro-motor reprocessing therapy, a novel therapeutic technique based on eye movement desensitization and reprocessing (EMDR), in reducing motion sickness. Based on visually induced motion sickness in two sets of performed sessions, eight participants were exposed to VRT stimulation in a VRT/non-VRT setting. Simultaneously, brain activity changes were recorded using electroencephalography (EEG) at baseline and during stimulus exposure, and comparisons made across the VRT/non-VRT conditions. A significant reduction in the alpha (8-12 Hz) spectral power was observed in the frontal and occipital locations, consistent across all participants. Furthermore, significant reductions were also found in the frontal and occipital delta (0.5-4 Hz) and theta (4-8 Hz) spectral power frequency bands between non-VRT and VRT conditions (p < 0.05). Our results offer novel insights for a potential nonpharmacological treatment and attenuation of motion sickness. Furthermore, symptoms can be observed, and alleviated, in real-time using the reported techniques. Clinical relevance - Instead of using drugs to treat motion sickness, patients could safely use this VRT technique.